Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov 16;18(1):1120.
doi: 10.1186/s12885-018-5058-2.

Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer

Xiaomin Ge  1 , Jingping Yu  2 , Zhongling Wang  3 , Yiqun Xu  1 , Changjie Pan  1 , Lu Jiang  1 , Yanling Yang  1 , Kai Yuan  4 , Wei Liu  5
Affiliations
Comparative Study

Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer

Xiaomin Ge et al. BMC Cancer. .

Abstract

Background: To compare dual energy CT iodine imaging and standardized iodine concentration before and after chemoradiotherapy (CRT) for esophageal cancer and evaluate the efficacy of CRT for EC by examining DECT iodine maps and standard CT values.

Methods: The clinical data of 45 patients confirmed by pathology with newly diagnosed esophageal cancer who underwent concurrent CRT from February 2012 to January 2017 in our department of radiology were collected. All patients underwent dual-source dual-energy CT (DECT) before and after CRT. Normalized iodine concentration (NIC) and normalized CT (NCT) corresponding to the overall cancer lesion and its maximum cross-sectional area were observed and compared. Additionally, 30 healthy individuals were compared as control group. After treatment, the patients were divided into two groups according to RECIST1.1: treatment effective group and ineffective group.

Results: There were 33 patients (CR 9, PR 24) in the effective group and 12 patients (SD 12, PD 0) in the ineffective group. There was no significant difference in the NIC-A, NIC-V, NCT-A and NCT-A indexes between the effective group (B group) and the ineffective group (C group) before treatment (P > 0.05). After the treatment, the above-mentioned indexes in the effective group of patients were significantly lower than before treatment, and compared with the ineffective group, the NIC-A, NIC-V, NCT-A and NCT-V values of the effective group were significantly lower than those of ineffective group (P < 0.05). After treatment, the NIC-V and NCT-V in the ineffective group were lower than before treatment, and the difference was statistically significant (P < 0.05). However, their NIC-A and NCT-A were not statistically different from those before treatment (P > 0.05).

Conclusion: Using DECT iodine map, the changes of NIC and NIC before and after CRT in patients with esophageal cancer can evaluate the effect of CRT, and does not increase the radiation dose, so it is suitable for clinical use.

Keywords: Chemoradiotherapy; Dual energy CT; Esophageal cancer; Iodine imaging.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

A written informed consent was obtained from all patients and the study protocol was approved by the ethics committee of Changzhou Second People’s Hospital Affiliated to Nanjing Medical University (No. KY201226).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
CT images of esophageal cancer before and after treatment. a The mucosal and aortic CT value of esophageal cancer before treatment; b The mucosal and aortic iodine values of esophageal cancer before treatment; c The mucosal and aortic CT value of esophageal cancer after treatment; d The mucosal and aortic iodine values of esophageal cancer after treatment
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;0:1–31. - PubMed
    1. Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14(4):249–258. - PubMed
    1. Liang J, E M WG, Zhao L, Li X, Xiu X, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase II clinical trial. Onco Targets Ther. 2013;6:1589–1596. doi: 10.2147/OTT.S50945. - DOI - PMC - PubMed
    1. Rankin S. Oesophageal cancer. In: Husband JES, Reznek RH, editors. Imaging in oncology. Oxford: Isis Medical Media; 1998. pp. 93–110.
    1. Machida H, Tanaka I, Fukui R, Shen Y, Ishikawa T, Tate E, et al. Dual-energy spectral CT: various clinical vascular applications. Radiographics. 2016;36(4):1215–1232. doi: 10.1148/rg.2016150185. - DOI - PubMed

Publication types